Acutaas Chemicals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
ACUTAAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Acutaas Chemicals Limited has confirmed to the exchanges that there has been no deviation or variation in the use of proceeds from its Preferential Issue of equity shares allotted on May 31, 2024. The company had raised a total of INR 99.099 Crores, of which INR 77.00 Crores was earmarked for capital expenditure related to electrolytes additives and allied business, and INR 22.099 Crores for general corporate purposes. As of June 30, 2025, the entire amount of INR 99.099 Crores has been fully utilized exactly as originally planned, with no changes to the stated objects. The Audit Committee and auditors have raised no objections, and the filing was signed by CFO Bhavin N. Shah.
This is a routine compliance filing and a positive signal for shareholders — it confirms that the company has stuck to its stated use of funds raised from investors, with full deployment completed on schedule. It reflects governance discipline and transparency, with no negative implications for the stock price.